ArticleOncotarget2017

Patient-derived ovarian cancer xenografts re-growing after a cisplatinum treatment are less responsive to a second drug re-challenge: a new experimental setting to study response to therapy.

Francesca Ricci et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.